Axsome Therapeutics (AXSM) Free Cash Flow Growth (1y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 60.84% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 88.70% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.72% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 66.37% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 3.98% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 137.65% |
| 10 | Axsome Therapeutics | 11.82 Bn | 11.51 Bn | 176.48 Mn | 52.37% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 52.37% |
| Dec 31, 2025 | 28.62% |
| Sep 30, 2025 | 105.28% |
| Jun 30, 2025 | -7.54% |
| Mar 31, 2025 | 18.39% |
| Dec 31, 2024 | 13.62% |
| Sep 30, 2024 | 65.28% |
| Jun 30, 2024 | 45.64% |
| Mar 31, 2024 | -809.11% |
| Dec 31, 2023 | -9.46% |
| Sep 30, 2023 | -136.24% |
| Jun 30, 2023 | -64.25% |
| Mar 31, 2023 | 82.07% |
| Dec 31, 2022 | 3.80% |
| Sep 30, 2022 | 15.58% |
| Jun 30, 2022 | -32.92% |
| Mar 31, 2022 | -20.63% |
| Dec 31, 2021 | -40.18% |
| Sep 30, 2021 | -71.66% |
| Jun 30, 2021 | -34.48% |
| Mar 31, 2021 | -17.02% |
| Dec 31, 2020 | -17.11% |
| Sep 30, 2020 | -48.16% |
| Jun 30, 2020 | -117.66% |
| Mar 31, 2020 | -145.10% |
| Dec 31, 2019 | -79.38% |
| Sep 30, 2019 | -79.55% |
| Jun 30, 2019 | -13.09% |
| Mar 31, 2019 | -41.88% |
| Dec 31, 2018 | -55.68% |
| Sep 30, 2018 | 8.22% |
| Jun 30, 2018 | -8.13% |
| Mar 31, 2018 | -0.84% |
| Dec 31, 2017 | 12.90% |
| Sep 30, 2017 | -32.23% |
| Jun 30, 2017 | -33.30% |
| Mar 31, 2017 | -67.73% |
| Dec 31, 2016 | -220.30% |
| Sep 30, 2016 | -153.19% |
| Jun 30, 2016 | -152.64% |
| Mar 31, 2016 | -238.57% |